The concurrent targeting of both PI3K and HER2 signaling pathways has shown effectiveness in treating HER2-positive BC, highlighting the potential of combination therapy in preventing BC associated with PI3K pathway dysregulation [125]. Here, PIK3CG is linked to breast cancer.